Tag Archive for: M&A

aicuris japan flag
M&A

Japan’s Asahi Kasei buys antiviral specialist Aicuris in €780 million deal

Takeover in Wuppertal: Aicuris Anti-Infective Cures AG, which specializes in active ingredients for infectious diseases, is being acquired by Japanese pharmaceutical company Asahi Kasei for almost €800 million (around US$920 million). The company, founded by former Bayer employees Helga Rübsamen-Schaeff and Holger Zimmermann using substances from Bayer, had obtained its own approval and is currently in late-stage clinical development with active ingredients that are currently being presented with positive data at scientific conferences.

Read more
Eli Lilly Abivax acquisition rumors
M&A

Eli Lilly-Abivax €15 billion takeover rumor stirs markets, but no formal steps confirmed

While much of the biotech industry is focused on meetings and dealmaking at the J.P. Morgan (JPM) Healthcare Conference, a rumor has cut through the JPM noise. The possibility of Eli Lilly making a move on Abivax is back on the table, with a price tag that would imply a valuation close to twice the French company’s current market capitalisation at €8.4 billion ($9.8 billion).

Read more
dark blue colors
M&A

Amgen acquires Dark Blue Therapeutics for up to $840 million

Amgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline. The specific breakdown of the upfront payment alongside development and regulatory milestones was not disclosed in the press release.

Read more
Schematic of uric acid crystal formation and swallowingJohn Kiel - wikipedia
M&A

Sobi strengthens gout pipeline with Arthrosi acquisition

Sobi AB has completed the US$1.5bn acquisition of Chinese Arthrosi Therapeutics Ltd. Its lead candidate, pozdeutinurad, a URAT1 inhibitor for gout, is in pivotal global Phase-III trials, with China licensing targeting approval by 2028.

Read more
Novo logoAdobe stock photos - https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/
M&A

Novo and Pfizer in Metsera takeover battle

Danish Novo Nordisk A/S has made an unexpected takeover bid for US biotech Metsera, Inc. This challenges the already agreed acquisition by Pfizer Inc. Novo offers US$6.5bn in cash, plus up to US$2.5bn in milestone payments. The total potential value is around US$9bn. Pfizer previously offered US$4.9bn plus US$2.4bn in milestones.

Read more
Novartis HQ in Basel, Switzerlandadobe stock photos - Michael Derrer Fuchs
M&A

Novartis acquires Avidity Biosciences for US$12bn

In a major bet on RNA medicine, Swiss Novartis AG announced to buy Avidity Biosciences Inc for US$12bn. Avidity’s Oligonucleotide Conjugate (AOC) platform allows Transferin receptor-targeted RNA delivery to muscle. With the acquisition Novartis secures access to three late-stage RNA drug candidates for muscular dystrophies.

Read more
Biopharma VC, M&A and deals recovered in Q3 25 vs Q2 25.adobe stock photos - Miha Creative
Financing/Partnering

VC investments rise nearly 71% in Q3 2025

VC investments in biotech rose 70.9% in Q3 2025 to US$3.1bn, driven by Series D growth, M&A activity, and Fed interest rate cuts, reports Global Data. J.P. Morgan reports same trends but different figures.

Read more
Ipsen HQIpsen SA
M&A

Ipsen acquires ImCheck in US$1bn deal

Pharma giant Ipsen will pay US$1bn to acquire French immuno-oncology firm ImCheck Therapeutics SAS. The deal includes US$350m upfront and up to US$650m in milestone payments. ImCheck focuses on butyrophilins, a new class of immune regulators, through its antibody programme ICT01, currently in Phase I trials.

Read more
Merus headquarters in Utrecht, The NetherlandsMerus NV
M&A

Genmab swallows Merus in US$8bn deal

Danish Genmab A/S has acquired the Dutch oncology specialist Merus NV for US$8bn in cash. The 41% premium over Merus’s share price at Friday is largely attributed to the bispecific EGFR x LGR5 antibody, Petosemtamab

Read more
Roche towers in BaselHenk Vrieselaar - stock.adobe.com
M&A

Roche acquires 89bio for US$3.5bn

Roche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin, an FGF21 analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). The deal is expected to close in Q4 2025.

Read more